不良事件报告

如果发生不良事件,患者应始终寻求医生或药剂师的建议。

如果您想向ELC Group s.r.o.报告不良事件,请在下面找到联系信息:

+420 224 910 672

(欧洲中部时间09.00-17.30)

+420 226 251 459

(24/7不间断)

有关其他任何问题,请与我们联系:

+420 22 491 0000或我们的 区域办事处。

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

ELC GROUP Advisory Board’s Dr. Paolo Biffignandi to write opinion column for industry leading publication

September 27th 2011 – ELC GROUP, the pan-European pharmaceutical regulatory affairs organisation, announced today that it would be working with the editorial team of European Pharmaceutical Manufacturer magazine to supply expert opinion on the regulatory affairs industry.

ELC GROUP’s Advisory Board member, Dr. Paolo Biffignandi MD, PhD, QPPV, FTOPRA, will write the regular column. Dr. Biffignandi has over 30 years’ experience in Regulatory Affairs and pharmacovigilance. He is a past President and now Fellow of The Organisation for Professionals in Regulatory Affairs (TOPRA) and a renowned physician, with PhDs in endocrinology and pharmacology. He is also an Overseas Fellow of the Royal Society of Medicine (UK).

EPM magazine (European Pharmaceutical Manufacturer) is now in its 11th year of publication and remains the only product tabloid-style publication in the field of pharmaceutical manufacture in Europe. It continues to uphold its reputation as a prime and, most importantly, trusted resource for the global pharmaceutical manufacturing industry by working with industry experts.

Speaking about working with EPM, Marco Rubinstein ELC GROUP CEO said: “We are very excited to be contributing to the market leading publication for the European manufacturing industry. Readers of EPM can expect to gain a real insight into pharmaceutical regulatory affairs thanks to Paolo’s vast experience and industry knowledge.

Editor of EPM Elizabeth Valero said: “I am excited to welcome Paolo on board as the first contributor to EPM’s new Regulatory Affairs column. His extensive experience in the field as former President of TOPRA and now as an advisory board member of ELC GROUP made him an ideal candidate. EPM readers can look forward to some very topical and informative submissions from Paolo, the first of which will focus on the impending anti-counterfeiting legislation and what this means for pharma manufacturers.”

The first column written by Paolo will appear in the October edition of EPM. For a free subscription to the magazine and to read all future Regulatory Affairs columns written by Paolo, please click here (http://www.epmmagazine.com/x/subscriberNew.html).